DrugDashboards

Marcaine

Bupivacaine Hydrochloride · BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL · Injection, Solution · Epidural; Retrobulbar · Hospira, Inc.

NDC 00409-1582-10 · 10 VIAL, SINGLE-DOSE in 1 TRAY / 10 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

17 companies supply this market — deep enough that no single failure threatens the supply. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$0.0110per billing unit (0.5 MG)HCPCS J0665 · Jul 1, 2026
  • Part D plans paid (avg)$0.1634per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal ceiling (Big4)$32.40per package of 10X10MLPfizer Inc. · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$52.21
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 0.5 MG
$0.011
HCPCS J0665 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$802
218 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for bupivacaine hydrochloride (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $10.06 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA016964
TE code
AP
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)Feb 20, 2018
    Discontinuation of the manufacture of the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)Feb 20, 2018
    Discontinuation of the manufacture of the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)Feb 20, 2018
    Discontinuation of the manufacture of the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months

Recalls (this NDC)

  • Class II · TerminatedSep 16, 2016
    Hospira Inc., A Pfizer Company — Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.
  • Class II · TerminatedSep 16, 2016
    Hospira Inc., A Pfizer Company — Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.
  • Class I · TerminatedJun 17, 2014
    Hospira Inc. — Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.
  • Class I · TerminatedApr 21, 2014
    Hospira Inc. — Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.
  • Class I · TerminatedOct 18, 2013
    Hospira Inc. — Presence of Particulate Matter: Units of this lot may have visible metal particles embedded in the vial and in the solution causing the product to be discolored.

Manufacturers of Bupivacaine Hydrochloride (Injection, Solution)

LabelerStrengthFirst seenLast seen
Asclemed USA, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Henry Schein, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Henry Schein, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
NorthStar RxLLCBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Onesource Specialty Pharma LimitedBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Onesource Specialty Pharma LimitedBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Onesource Specialty Pharma LimitedBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Xellia Pharmaceuticals USA LLCBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Xellia Pharmaceuticals USA LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
A-S Medication SolutionsBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Fosun Pharma USA Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Fosun Pharma USA Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, IncBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, IncBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 225 mg/30mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 150 mg/30mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 25 mg/10mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 250 mg/50mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 50 mg/10mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 75 mg/30mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Marcaine — NDC 00409-1582-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00409158210.

Free to cite with attribution — see how the data is put together.